Stock-research Ratings: Great Lakes Dredge & Dock Corporation (GLDD), Supernus Pharmaceuticals, Inc. (SUPN)

Great Lakes Dredge & Dock Corporation (NASDAQ:GLDD) tinted gains of +1% (+0.07 points) to US$7.08. The volume of 0.19 Million shares climbed down over an trading activity of 319.58 Million shares. EPS ratio determined by looking at last 12 month figures is -0.38. Over the same time span, the stock marked US$7.94 as its best level and the lowest price reached was US$4.25. The corporation has a market cap of US$438.54 Million.

Great Lakes Dredge & Dock Corporation (NASDAQ:GLDD)’s earnings per share has been growing at a -46.6 percent rate over the past 5 year when average revenue increase was noted as 3.6 percent. The return on equity ratio or ROE stands at -3.4 percent while most common profitability ratio return on investment (ROI) was -0.9 percent. The company’s institutional ownership is monitored at 83.4 percent. The company’s net profit margin has achieved the current level of -1.1 percent and possesses 10.1 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 0 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 1 think it is Hold. Recently, analysts have updated the overall rating to 2.5. 1 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) is worth US$2.02 Billion and has recently risen 2.05% to US$38.24. The latest exchange of 0.34 Million shares is below its average trading activity of 588.97 Million shares. The day began at US$38.23 but the price moved to US$38.23 at one point during the trading and finally capitulating to a session high of US$38.23. The stock tapped a 52-week high of US$61.25 while the mean 12-month price target for the shares is US$59.67.

Currently, the stock carries a price to earnings ratio of 19.02, a price to book ratio of 4.73, and a price to sales ratio of 5.29. For the past 5 years, the company’s revenue has grown 189.7%, while the company’s earnings per share has grown 19.7%. With an institutional ownership near 0%, it carries an earnings per share ratio of 2.01.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 4 brokerage firms polled by Factset Research. At present, 1 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 4 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.67.